TABLE 6

Multivariate analysis of prognostic factors for overall survival in EGFR mutant patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)

Factors	Patients n	Median overall survival months	Univariate analysis p-value	Multivariate analysis
Factors	Patients n	Median overall survival months	Univariate analysis p-value	Hazard ratio (95% CI)	p-value
Age years			<0.001
≤50	81	20.7		1
51–60	117	31.5		0.66 (0.47–0.92)	0.015
61–70	134	26.3		0.69 (0.50–0.95)	0.025
71–80	128	19.0		0.82 (0.59–1.15)	0.246
>80	64	14.3		0.73 (0.49–1.11)	0.142
Sex			0.079
Female	308	25.3		1
Male	216	22.4		1.25 (0.99–1.57)	0.065
Smoking history			0.002
Never-smoker	419	25.0		1
Ex-smoker	52	30.3		0.96 (0.67–1.37)	0.801
Current smoker	53	15.4		1.66 (1.17–2.36)	0.005
ECOG PS			<0.001
0–1	449	27.0		1
2–4	75	11.0		2.84 (2.13–3.78)	<0.001
EGFR mutation			0.060
Uncommon	63	19.0		1
Del-19	233	27.9		0.81 (0.59–1.11)	0.193
L858R	228	23.1		0.93 (0.68–1.27)	0.634
TKI sequence			<0.001
First-line	340	19.5		1
Second-line	117	28.0		0.70 (0.54–0.91)	0.007
Third-line or greater	67	34.7		0.58 (0.43–0.78)	<0.001
Platinum use			<0.001
No	224	15.4		1
Yes	300	30.3		0.85 (0.65–1.11)	0.232
Pemetrexed use			<0.001
No	252	15.2		1
Yes	272	32.2		0.57 (0.45–0.72)	<0.001

ECOG PS: Eastern Cooperative Oncology Group performance status.